Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 0.47 |
| ▸ | AURKA | O14965 | 9/20 | 0.47 |
| ▸ | GSK3A | P49840 | 8/20 | 0.47 |
| ▸ | JAK2 | O60674 | 3/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.44 |
| ▸ | MARK3 | P27448 | 1/20 | 0.44 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3583884 | 1.00 | GSK3B (0.47) | GSK3BAURKAGSK3AJAK2AURKB | |
| SCHEMBL3583888 | 1.00 | GSK3B (0.47) | GSK3BAURKAGSK3AJAK2AURKB | |
| SCHEMBL3587815 | 0.90 | MARK3 (0.42) | AURKAAURKBMARK3MARK4 | |
| SCHEMBL3585284 | 0.90 | AURKA (0.47) | AURKAAURKBMARK3MARK4 | |
| SCHEMBL1353831 | 0.87 | MARK3 (0.41) | GSK3BAURKAGSK3AJAK2AURKB | |
| SCHEMBL1355702 | 0.86 | AURKA (0.45) | AURKAJAK2AURKBMARK3MARK4 | |
| SCHEMBL3579216 | 0.86 | JAK3 (0.50) | AURKAJAK2MARK3MARK4 | |
| SCHEMBL1355699 | 0.86 | AURKA (0.45) | AURKAJAK2AURKBMARK3MARK4 | |
| SCHEMBL3587338 | 0.86 | MARK3 (0.42) | AURKAAURKBMARK3MARK4 | |
| SCHEMBL3585565 | 0.86 | MARK3 (0.42) | AURKAAURKBMARK3MARK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190787-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC | 2010-07-29 | — | — | US | claimed |
| EP-2108019-A2 | 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | Biogen Idec MA, Inc. (US) | 2009-10-14 | — | — | EP | claimed |
| WO-2008094575-A2 | 1-H-PYRAZOLO(3,4B)PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | BIOGEN IDEC MA INC. (US) | 2008-08-07 | — | — | WO | claimed |
| US-20100190787-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190787-A1 | Modulators of Mitotic Kinases | CDK1, BUB1, BUB1B | GSK3B 116/4885AURKA 10/4885GSK3A 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.